Erenumab Production Cost Reports

The report provides a detailed analysis essential for establishing an erenumab production plant. It encompasses all critical aspects necessary for erenumab production, including the cost of erenumab production, erenumab plant cost, erenumab production costs, and the overall erenumab production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an erenumab production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Erenumab, marketed as Aimovig, is a fully human monoclonal antibody used in pharmaceutical applications for the preventive treatment of migraines in adults by antagonising the calcitonin gene-related peptide receptor (CGRP-R), which plays an important role in migraine pathophysiology. It is developed by Amgen and Novartis and administered via subcutaneous injection using pre-filled syringes or autoinjectors, at doses of 70 mg or 140 mg monthly. It showed significant reductions in monthly migraine days in clinical trials, such as a mean decrease of 3.7 days at 70 mg compared to placebo.

Erenumab’s market drivers include its status as the first FDA-approved CGRP receptor antagonist for migraine prevention, driving first-mover advantage. The rising prevalence of chronic and episodic migraines, affecting millions globally, boosts the market demand. The expanding clinical evidence of efficacy, such as significant reductions in monthly migraine days, and growing adoption as a first-line preventive therapy with convenient self-administered monthly injections fuels the market expansion. Additional factors include increased healthcare spending on neurological disorders, improved insurance reimbursement and patient access, advancements in CGRP inhibitors, and partnerships like Amgen-Novartis for global commercialisation. However, regulatory approvals from agencies like the FDA, EMA, and TGA impact industrial erenumab procurement, with criteria limiting use to adults with at least 4-8 migraine days per month who failed prior prophylactics, affecting eligible patient volumes and market access.

Raw Material for Erenumab Production

According to the erenumab production plant project report, the various raw materials for erenumab production include Chinese hamster ovary cells.

Production Process of Erenumab

The extensive erenumab production cost report consists of the following major industrial production process:

1. Production via recombinant DNA transfection: The production process of erenumab starts with recombinant DNA transfection of Chinese hamster ovary (CHO) cells using plasmids encoding the antibody genes, followed by selection and cloning of high-producing lines in nutrient-limited media. The chosen clones are cultured in serum-free suspension within fed-batch bioreactors at high densities (10-15 million cells/mL), optimising pH, temperature, oxygen, and feeds. The harvested supernatant undergoes multi-step purification via protein A affinity, ion-exchange, hydrophobic interaction, and size-exclusion chromatography, along with viral inactivation, nanofiltration, and low-pH treatment for >99% purity. The final steps include ultrafiltration/diafiltration, aseptic filling into syringes/autoinjectors, and QC testing by peptide mapping (ESI-MS/MS), HPLC for aggregates/degradation, and bioassays.

Erenumab, marketed as Aimovig, is a fully human IgG2 monoclonal antibody with a molecular weight of 150 kDa, having two heavy chains (456 amino acids each, 4 intrachain disulfide bonds) and two lambda light chains (216 amino acids each, 2 intrachain disulfide bonds). It is formulated as a sterile, preservative-free, clear to opalescent, colourless to light-yellow aqueous solution at 70 mg/mL or 140 mg/mL (pH 5.2). It is stabilised with acetate, sucrose, and polysorbate 80 for subcutaneous injection via pre-filled syringes or autoinjectors. It is produced recombinantly in CHO cells and possesses non-linear pharmacokinetics with 82% subcutaneous bioavailability, peak plasma levels in 4-6 days, and a 28-day elimination half-life through proteolysis. It also maintains stability against degradation, such as isomerisation.